BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Romero-Gómez M, Fernández-Rodríguez CM, Andrade RJ, Diago M, Alonso S, Planas R, Solá R, Pons JA, Salmerón J, Barcena R. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol. 2008;48:721-727. [PMID: 18308416 DOI: 10.1016/j.jhep.2007.11.022] [Cited by in Crossref: 133] [Cited by in F6Publishing: 114] [Article Influence: 10.2] [Reference Citation Analysis]
Number Citing Articles
1 Vespasiani-Gentilucci U, Gallo P, De Vincentis A, Galati G, Picardi A. Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis. World J Gastroenterol. 2014;20:2825-2838. [PMID: 24659875 DOI: 10.3748/wjg.v20.i11.2825] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
2 Bo Q, Orsenigo R, Wang J, Griffel L, Brass C. Glucose abnormalities in Asian patients with chronic hepatitis C. Drug Des Devel Ther 2015;9:6009-17. [PMID: 26609222 DOI: 10.2147/DDDT.S92060] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 van der Meer AJ, Berenguer M. Reversion of disease manifestations after HCV eradication. Journal of Hepatology 2016;65:S95-S108. [DOI: 10.1016/j.jhep.2016.07.039] [Cited by in Crossref: 100] [Cited by in F6Publishing: 86] [Article Influence: 20.0] [Reference Citation Analysis]
4 Katsi V, Felekos I, Skevofilax S, Aggeli C, Tousoulis D, Stefanadis C, Kallikazaros I. Cardiovascular Disease and Hepatitis C Virus Infection: An Irrelevant Statement or a Hot Relationship? Cardiology in Review 2015;23:11-7. [DOI: 10.1097/crd.0000000000000031] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
5 Kawaguchi Y, Mizuta T, Oza N, Takahashi H, Ario K, Yoshimura T, Eguchi Y, Ozaki I, Hisatomi A, Fujimoto K. Eradication of hepatitis C virus by interferon improves whole-body insulin resistance and hyperinsulinaemia in patients with chronic hepatitis C. Liver Int. 2009;29:871-877. [PMID: 19302179 DOI: 10.1111/j.1478-3231.2009.01993.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
6 Stine JG, Wynter JA, Niccum B, Kelly V, Caldwell SH, Shah NL. Effect of Treatment with Direct Acting Antiviral on Glycemic Control in Patients with Diabetes Mellitus and Chronic Hepatitis C. Ann Hepatol 2017;16:215-20. [PMID: 31153414 DOI: 10.5604/16652681.1231581] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
7 Eslam M, Kawaguchi T, Del Campo JA, Sata M, Khattab MA, Romero-Gomez M. Use of HOMA-IR in hepatitis C. J Viral Hepat. 2011;18:675-684. [PMID: 21914084 DOI: 10.1111/j.1365-2893.2011.01474.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
8 Lo Y, Chang S, Sheng W, Hung C, Chang S. Association of pancreatic autoantibodies and human leukocyte antigen haplotypes with resolution of diabetes mellitus after therapy for hepatitis C virus infection in patients with HIV infection: case report and review of literature: . European Journal of Gastroenterology & Hepatology 2009;21:478-81. [DOI: 10.1097/meg.0b013e328317f4c8] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
9 Eslam M, Aparcero R, Kawaguchi T, Del Campo JA, Sata M, Khattab MA, Romero-gomez M. Meta-analysis: insulin resistance and sustained virological response in hepatitis C: Meta-analysis: insulin resistance and sustained virological response in hepatitis C. Alimentary Pharmacology & Therapeutics 2011;34:297-305. [DOI: 10.1111/j.1365-2036.2011.04716.x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 72] [Article Influence: 7.9] [Reference Citation Analysis]
10 Butt AA, Yan P, Aslam S, Shaikh OS, Abou-Samra AB. Hepatitis C Virus (HCV) Treatment With Directly Acting Agents Reduces the Risk of Incident Diabetes: Results From Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES). Clin Infect Dis 2020;70:1153-60. [PMID: 30977808 DOI: 10.1093/cid/ciz304] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
11 Ampuero J, Romero-Gómez M, Reddy KR. Review article: HCV genotype 3 – the new treatment challenge. Aliment Pharmacol Ther. 2014;39:686-698. [PMID: 24612116 DOI: 10.1111/apt.12646] [Cited by in Crossref: 81] [Cited by in F6Publishing: 73] [Article Influence: 11.6] [Reference Citation Analysis]
12 Sevastianos VA, Voulgaris TA, Dourakis SP. Hepatitis C, systemic inflammation and oxidative stress: correlations with metabolic diseases. Expert Review of Gastroenterology & Hepatology 2020;14:27-37. [DOI: 10.1080/17474124.2020.1708191] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
13 Duarte-rojo A, Heathcote EJ, Feld JJ. ‘Easy to treat’ genotypes were not created equal: Can rapid virological response (RVR) level the playing field? Journal of Hepatology 2011;55:466-73. [DOI: 10.1016/j.jhep.2011.02.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
14 Pattullo V, Heathcote J. Hepatitis C and diabetes: one treatment for two diseases? Liver Int. 2010;30:356-364. [PMID: 20040049 DOI: 10.1111/j.1478-3231.2009.02185.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
15 Naing C, Mak JW, Wai N, Maung M. Diabetes and infections-hepatitis C: is there type 2 diabetes excess in hepatitis C infection? Curr Diab Rep. 2013;13:428-434. [PMID: 23463119 DOI: 10.1007/s11892-013-0370-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
16 Eslam M, Khattab MA, Harrison SA. Peroxisome proliferator-activated receptors and hepatitis C virus. Therap Adv Gastroenterol 2011;4:419-31. [PMID: 22043232 DOI: 10.1177/1756283X11405251] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
17 Bose SK, Ray R. Hepatitis C virus infection and insulin resistance. World J Diabetes. 2014;5:52-58. [PMID: 24567801 DOI: 10.4239/wjd.v5.i1.52] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 54] [Article Influence: 8.4] [Reference Citation Analysis]
18 Gastaldi G, Gomes D, Schneiter P, Montet X, Tappy L, Clément S, Negro F. Treatment with direct-acting antivirals improves peripheral insulin sensitivity in non-diabetic, lean chronic hepatitis C patients. PLoS One 2019;14:e0217751. [PMID: 31170218 DOI: 10.1371/journal.pone.0217751] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
19 Negro F, Forton D, Craxì A, Sulkowski MS, Feld JJ, Manns MP. Extrahepatic Morbidity and Mortality of Chronic Hepatitis C. Gastroenterology 2015;149:1345-60. [DOI: 10.1053/j.gastro.2015.08.035] [Cited by in Crossref: 221] [Cited by in F6Publishing: 192] [Article Influence: 36.8] [Reference Citation Analysis]
20 Thompson AJ, Patel K, Chuang WL, Lawitz EJ, Rodriguez-Torres M, Rustgi VK, Flisiak R, Pianko S, Diago M, Arora S, Foster GR, Torbenson M, Benhamou Y, Nelson DR, Sulkowski MS, Zeuzem S, Pulkstenis E, Subramanian GM, McHutchison JG;  ACHIEVE-1 and ACHIEVE-2/3 Study Teams. Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. Gut. 2012;61:128-134. [PMID: 21873466 DOI: 10.1136/gut.2010.236158] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 5.6] [Reference Citation Analysis]
21 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55:245-264. [PMID: 21371579 DOI: 10.1016/j.jhep.2011.02.023] [Cited by in Crossref: 847] [Cited by in F6Publishing: 781] [Article Influence: 84.7] [Reference Citation Analysis]
22 Lerat H, Imache MR, Polyte J, Gaudin A, Mercey M, Donati F, Baudesson C, Higgs MR, Picard A, Magnan C, Foufelle F, Pawlotsky JM. Hepatitis C virus induces a prediabetic state by directly impairing hepatic glucose metabolism in mice. J Biol Chem. 2017;292:12860-12873. [PMID: 28559285 DOI: 10.1074/jbc.m117.785030] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
23 Jamall IS, Yusuf S, Azhar M, Jamall S. Is pegylated interferon superior to interferon, with ribavarin, in chronic hepatitis C genotypes 2/3? World J Gastroenterol 2008;14:6627-31. [PMID: 19034963 DOI: 10.3748/wjg.14.6627] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
24 Arase Y, Suzuki F, Kobayashi M, Suzuki Y, Kawamura Y, Matsumoto N, Akuta N, Imai N, Kobayashi M, Sezaki H. Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus. Hepatol Res. 2011;41:524-529. [PMID: 21435130 DOI: 10.1111/j.1872-034x.2011.00798.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
25 Milner K, Chisholm D, George J. The many faces of hepatitis C: Liver disease and type 2 diabetes. Hepatology 2009;50:668-70. [DOI: 10.1002/hep.23117] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
26 Younossi ZM, Kanwal F, Saab S, Brown KA, El-Serag HB, Kim WR, Ahmed A, Kugelmas M, Gordon SC. The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Ther. 2014;39:518-531. [PMID: 24461160 DOI: 10.1111/apt.12625] [Cited by in Crossref: 94] [Cited by in F6Publishing: 89] [Article Influence: 13.4] [Reference Citation Analysis]
27 Yunihastuti E, Hariyanto R, Sulaiman AS, Harimurti K. Hepatitis C continuum of care: Experience of integrative hepatitis C treatment within a human immunodeficiency virus clinic in Indonesia. PLoS One 2021;16:e0256164. [PMID: 34383853 DOI: 10.1371/journal.pone.0256164] [Reference Citation Analysis]
28 Wigneswaran J, Van Wyck D, Pegues D, Gholam P, Nissenson AR. Hepatitis C virus infection in patients with end-stage renal disease: Hepatitis C in renal patients. Hemodialysis International 2018;22:297-307. [DOI: 10.1111/hdi.12672] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
29 Yen YH, Lin MT, Kuo FY, Chang KC, Tsai MC, Tseng PL, Wu CK, Lin JT, Hu TH, Lu SN, Wang JH, Hung CH, Chen CH. The association between steatosis and diabetes with hepatocellular carcinoma in non-genotype 3 chronic hepatitis C patients. Liver Int 2018;38:1064-73. [PMID: 29164767 DOI: 10.1111/liv.13633] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
30 Gane EJ. Diabetes mellitus following liver transplantation in patients with hepatitis C virus: risks and consequences. Am J Transplant. 2012;12:531-538. [PMID: 22123496 DOI: 10.1111/j.1600-6143.2011.03854.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
31 Zhao Y, Xing H. A Different Perspective for Management of Diabetes Mellitus: Controlling Viral Liver Diseases. J Diabetes Res 2017;2017:5625371. [PMID: 28352640 DOI: 10.1155/2017/5625371] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
32 Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Hirakawa M, Ikeda K, Kumada H. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology. 2009;49:739-744. [PMID: 19127513 DOI: 10.1002/hep.22703] [Cited by in Crossref: 195] [Cited by in F6Publishing: 167] [Article Influence: 16.3] [Reference Citation Analysis]
33 Romero-Gómez M, Diago M, Andrade RJ, Calleja JL, Salmerón J, Fernández-Rodríguez CM, Solà R, García-Samaniego J, Herrerías JM, De la Mata M, Moreno-Otero R, Nuñez O, Olveira A, Durán S, Planas R; Spanish Treatment of Resistance to Insulin in Hepatitis C Genotype 1 Group. Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology 2009;50:1702-8. [PMID: 19845037 DOI: 10.1002/hep.23206] [Cited by in Crossref: 109] [Cited by in F6Publishing: 98] [Article Influence: 9.1] [Reference Citation Analysis]
34 Chien CH, Lin CL, Hu CC, Chang JJ, Chien RN. Clearance of Hepatitis C Virus Improves Insulin Resistance During and After Peginterferon and Ribavirin Therapy. J Interferon Cytokine Res. 2015;35:981-989. [PMID: 26308911 DOI: 10.1089/jir.2014.0200] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
35 Shlomai A, Rechtman MM, Burdelova EO, Zilberberg A, Hoffman S, Solar I, Fishman S, Halpern Z, Sklan EH. The metabolic regulator PGC-1α links hepatitis C virus infection to hepatic insulin resistance. J Hepatol. 2012;57:867-873. [PMID: 22732512 DOI: 10.1016/j.jhep.2012.06.021] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
36 Loria P, Marchesini G, Nascimbeni F, Ballestri S, Maurantonio M, Carubbi F, Ratziu V, Lonardo A. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. Atherosclerosis 2014;232:99-109. [DOI: 10.1016/j.atherosclerosis.2013.10.030] [Cited by in Crossref: 78] [Cited by in F6Publishing: 65] [Article Influence: 11.1] [Reference Citation Analysis]
37 Petta S, Adinolfi LE, Fracanzani AL, Rini F, Caldarella R, Calvaruso V, Cammà C, Ciaccio M, Di Marco V, Grimaudo S, Licata A, Marrone A, Nevola R, Pipitone RM, Pinto A, Rinaldi L, Torres D, Tuttolomondo A, Valenti L, Fargion S, Craxì A. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. J Hepatol 2018;69:18-24. [PMID: 29505844 DOI: 10.1016/j.jhep.2018.02.015] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 19.3] [Reference Citation Analysis]
38 Gilad A, Fricker ZP, Hsieh A, Thomas DD, Zahorian T, Nunes DP. Sustained Improvement in Type 2 Diabetes Mellitus is Common After Treatment of Hepatitis C Virus With Direct-acting Antiviral Therapy. J Clin Gastroenterol 2019;53:616-20. [PMID: 30614943 DOI: 10.1097/MCG.0000000000001168] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
39 Kaddai V, Negro F. Current understanding of insulin resistance in hepatitis C. Expert Review of Gastroenterology & Hepatology 2014;5:503-16. [DOI: 10.1586/egh.11.43] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 4.6] [Reference Citation Analysis]
40 Aghemo A, Prati GM, Rumi MG, Soffredini R, D'Ambrosio R, Orsi E, De Nicola S, Degasperi E, Grancini V, Colombo M. Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C. Hepatology. 2012;56:1681-1687. [PMID: 22619107 DOI: 10.1002/hep.25867] [Cited by in Crossref: 71] [Cited by in F6Publishing: 65] [Article Influence: 7.9] [Reference Citation Analysis]
41 Aronsohn A, Reau N. Long-term Outcomes After Treatment With Interferon and Ribavirin in HCV Patients. Journal of Clinical Gastroenterology 2009;43:661-71. [DOI: 10.1097/mcg.0b013e31819f66e2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
42 Degasperi E, Aghemo A, Colombo M. Treatment of Extrahepatic Manifestations of Hepatitis C Virus. Clin Liver Dis 2017;21:631-43. [PMID: 28689598 DOI: 10.1016/j.cld.2017.03.015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
43 Douglas MW, George J. Molecular mechanisms of insulin resistance in chronic hepatitis C. World J Gastroenterol 2009;15:4356-64. [PMID: 19764085 DOI: 10.3748/wjg.15.4356] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 38] [Article Influence: 3.7] [Reference Citation Analysis]
44 Iwasa M, Mifuji-Moroka R, Hara N, Ishidome M, Iwata K, Sugimoto R, Tanaka H, Fujita N, Kobayashi Y, Takei Y. Visceral fat volume predicts new-onset type 2 diabetes in patients with chronic hepatitis C. Diabetes Res Clin Pract 2011;94:468-70. [PMID: 22014765 DOI: 10.1016/j.diabres.2011.09.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
45 Negro F. Steatosis and insulin resistance in response to treatment of chronic hepatitis C. J Viral Hepat. 2012;19 Suppl 1:42-47. [PMID: 22233413 DOI: 10.1111/j.1365-2893.2011.01523.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
46 Vanni E, Bugianesi E, Saracco G. Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: Myth or reality? Digestive and Liver Disease 2016;48:105-11. [DOI: 10.1016/j.dld.2015.10.016] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 7.4] [Reference Citation Analysis]
47 Jacobson IM, Cacoub P, Dal Maso L, Harrison SA, Younossi ZM. Manifestations of chronic hepatitis C virus infection beyond the liver. Clin Gastroenterol Hepatol. 2010;8:1017-1029. [PMID: 20870037 DOI: 10.1016/j.cgh.2010.08.026] [Cited by in Crossref: 108] [Cited by in F6Publishing: 96] [Article Influence: 9.8] [Reference Citation Analysis]
48 Innes HA, McDonald SA, Dillon JF, Allen S, Hayes PC, Goldberg D, Mills PR, Barclay ST, Wilks D, Valerio H, Fox R, Bhattacharyya D, Kennedy N, Morris J, Fraser A, Stanley AJ, Bramley P, Hutchinson SJ. Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes. Hepatology. 2015;62:355-364. [PMID: 25716707 DOI: 10.1002/hep.27766] [Cited by in Crossref: 77] [Cited by in F6Publishing: 78] [Article Influence: 12.8] [Reference Citation Analysis]
49 Drazilova S, Janicko M, Skladany L, Kristian P, Oltman M, Szantova M, Krkoska D, Mazuchova E, Piesecka L, Vahalova V, Rac M, Schreter I, Virag L, Koller T, Liptakova A, Ondrasova M, Jarcuska P. Glucose Metabolism Changes in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals. Can J Gastroenterol Hepatol 2018;2018:6095097. [PMID: 30402450 DOI: 10.1155/2018/6095097] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
50 Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis. 2011;52:889-900. [PMID: 21427396 DOI: 10.1093/cid/cir076] [Cited by in Crossref: 161] [Cited by in F6Publishing: 159] [Article Influence: 16.1] [Reference Citation Analysis]
51 Negro F. Mechanisms of hepatitis C virus-related insulin resistance. Clin Res Hepatol Gastroenterol. 2011;35:358-363. [PMID: 21354385 DOI: 10.1016/j.clinre.2011.01.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
52 Wang LS, D'Souza LS, Jacobson IM. Hepatitis C-A clinical review. J Med Virol. 2016;88:1844-1855. [PMID: 27097298 DOI: 10.1002/jmv.24554] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
53 Russo FP, Zanetto A, Gambato M, Bortoluzzi I, Al Zoairy R, Franceschet E, De Marchi F, Marzi L, Lynch EN, Floreani A, Farinati F, Schaefer B, Burra P, Zoller H, Mega A. Hepatitis C virus eradication with direct-acting antiviral improves insulin resistance. J Viral Hepat 2020;27:188-94. [PMID: 31596996 DOI: 10.1111/jvh.13215] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
54 Muñoz-Hernández R, Ampuero J, Millán R, Gil-Gómez A, Rojas Á, Macher HC, Gallego-Durán R, Gato S, Montero-Vallejo R, Rico MC, Maya-Miles D, Sánchez-Torrijos Y, Soria IC, Stiefel P, Romero-Gómez M. Hepatitis C Virus Clearance by Direct-Acting Antivirals Agents Improves Endothelial Dysfunction and Subclinical Atherosclerosis: HEPCAR Study. Clin Transl Gastroenterol 2020;11:e00203. [PMID: 32955194 DOI: 10.14309/ctg.0000000000000203] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
55 Li J, Zhang T, Gordon SC, Rupp LB, Trudeau S, Holmberg SD, Moorman AC, Spradling PR, Teshale EH, Boscarino JA, Schmidt MA, Daida YG, Lu M; CHeCS Investigators. Impact of sustained virologic response on risk of type 2 diabetes among hepatitis C patients in the United States. J Viral Hepat. 2018;25:952-958. [PMID: 29478263 DOI: 10.1111/jvh.12887] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 6.3] [Reference Citation Analysis]
56 Hsu C, Liu C, Liu C, Hsu S, Chen C, Hwang J, Lai M, Chen P, Chen D, Kao J. Association of metabolic profiles with hepatic fibrosis in chronic hepatitis C patients with genotype 1 or 2 infection: Metabolic profiles and hepatic fibrosis. Journal of Gastroenterology and Hepatology 2010;25:970-7. [DOI: 10.1111/j.1440-1746.2009.06186.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
57 van der Meer AJ. Achieving sustained virological response: what’s the impact on further hepatitis C virus-related disease? Expert Review of Gastroenterology & Hepatology 2015;9:559-66. [DOI: 10.1586/17474124.2015.1001366] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
58 Chirikov VV, Shaya FT, Howell CD. Association between interferon use and reduced metabolic and vascular complications among patients with hepatitis C. Expert Rev Gastroenterol Hepatol 2014;8:973-83. [PMID: 25109401 DOI: 10.1586/17474124.2014.945911] [Reference Citation Analysis]
59 Hamed AE, Elsahar M, Elwan NM, El-nakeep S, Naguib M, Soliman HH, Ahmed Aboubakr A, Abdelmaqsod A, Sedrak H, Assaad SN, Elwakil R, Esmat G, Salh S, Mostafa T, Mogawer S, Sadek SE, Saber MM, Ezelarab H, Mahmoud AA, Sultan S, El Kassas M, Kamal E, Elsayed NM, moussa S. Managing diabetes and liver disease association. Arab Journal of Gastroenterology 2018;19:166-79. [DOI: 10.1016/j.ajg.2018.08.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
60 Takahashi H, Nakahara T, Kogiso T, Imajo K, Kessoku T, Kawaguchi T, Ide T, Kawanaka M, Hyogo H, Fujii H, Ono M, Kamada Y, Sumida Y, Anzai K, Shimizu M, Torimura T, Nakajima A, Tokushige K, Chayama K, Eguchi Y; Japan Study Group of NAFLD (JSG‐NAFLD). Eradication of hepatitis C virus with direct-acting antivirals improves glycemic control in diabetes: A multicenter study. JGH Open 2021;5:228-34. [PMID: 33553660 DOI: 10.1002/jgh3.12474] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Chehadeh W, Al-Nakib W. Severity of liver disease predicts the development of glucose abnormalities in patients with chronic hepatitis B or C following achievement of sustained virological response to antiviral therapy. J Med Virol 2009;81:610-8. [PMID: 19235842 DOI: 10.1002/jmv.21396] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
62 Compagnoni S, Bruno EM, Madonia G, Cannizzaro M, Madonia S. Direct antiviral agents in hepatitis C virus related liver disease: Don't count the chickens before they're hatched. World J Gastroenterol 2021;27:2771-83. [PMID: 34135553 DOI: 10.3748/wjg.v27.i21.2771] [Reference Citation Analysis]
63 Nuño Solinís R, Arratibel Ugarte P, Rojo A, Sanchez Gonzalez Y. Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence. Infect Dis Ther 2016;5:491-508. [PMID: 27783223 DOI: 10.1007/s40121-016-0134-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
64 Cárdaba-García ME, Abad-Lecha E, Calleja-Hernández MÁ. Effectiveness of direct-acting antiviral drugs against hepatitis C virus: predictive factors of response to the treatment. Libyan J Med 2021;16:1949797. [PMID: 34308801 DOI: 10.1080/19932820.2021.1949797] [Reference Citation Analysis]
65 Watt KD, Dierkhising R, Fan C, Heimbach JK, Tillman H, Goldstein D, Thompson A, Krishnan A, Charlton MR. Investigation of PNPLA3 and IL28B genotypes on diabetes and obesity after liver transplantation: insight into mechanisms of disease. Am J Transplant. 2013;13:2450-2457. [PMID: 23859071 DOI: 10.1111/ajt.12355] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
66 Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol. 2008;49:634-651. [PMID: 18715665 DOI: 10.1016/j.jhep.2008.07.013] [Cited by in Crossref: 225] [Cited by in F6Publishing: 212] [Article Influence: 17.3] [Reference Citation Analysis]
67 Veldt BJ, Duarte-Rojo A, Thompson AJ, Watt KD, Heimbach JK, Tillmann HL, Goldstein DD, McHutchison JG, Charlton MR. Recipient IL28B polymorphism is an important independent predictor of posttransplant diabetes mellitus in liver transplant patients with chronic hepatitis C. Am J Transplant. 2012;12:737-744. [PMID: 22300408 DOI: 10.1111/j.1600-6143.2011.03843.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
68 Gualerzi A, Bellan M, Smirne C, Tran Minh M, Rigamonti C, Burlone ME, Bonometti R, Bianco S, Re A, Favretto S, Bellomo G, Minisini R, Carnevale Schianca GP, Pirisi M. Improvement of insulin sensitivity in diabetic and non diabetic patients with chronic hepatitis C treated with direct antiviral agents. PLoS One 2018;13:e0209216. [PMID: 30571711 DOI: 10.1371/journal.pone.0209216] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
69 Kumar A, Gupta V, Sharma P, Bansal N, Singla V, Arora A. Association of Overt Diabetes Mellitus with the Non-CC but not the CC Genotype of Interleukin-28B in Hepatitis C Virus Infected Patients. J Clin Transl Hepatol 2016;4:26-31. [PMID: 27047769 DOI: 10.14218/JCTH.2016.00040] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
70 Ampuero J, Romero-Gómez M. Assessing cardiovascular risk in hepatitis C: An unmet need. World J Hepatol. 2015;7:2214-2219. [PMID: 26380047 DOI: 10.4254/wjh.v7.i19.2214] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
71 Degasperi E, Aghemo A, Colombo M. Daclatasvir for the treatment of chronic hepatitis C. Expert Opinion on Pharmacotherapy 2015;16:2679-88. [DOI: 10.1517/14656566.2015.1109631] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
72 Giordanino C, Bugianesi E, Smedile A, Ciancio A, Abate ML, Olivero A, Pellicano R, Cassader M, Gambino R, Bo S, Ciccone G, Rizzetto M, Saracco G. Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study. Am J Gastroenterol. 2008;103:2481-2487. [PMID: 18702647 DOI: 10.1111/j.1572-0241.2008.02002.x] [Cited by in Crossref: 68] [Cited by in F6Publishing: 58] [Article Influence: 5.2] [Reference Citation Analysis]
73 Butt AA, Umbleja T, Andersen JW, Sherman KE, Chung RT; ACTG A5178 Study Team. Impact of peginterferon alpha and ribavirin treatment on lipid profiles and insulin resistance in Hepatitis C virus/HIV-coinfected persons: the AIDS Clinical Trials Group A5178 Study. Clin Infect Dis 2012;55:631-8. [PMID: 22563020 DOI: 10.1093/cid/cis463] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
74 Adinolfi LE, Nevola R, Guerrera B, D'Alterio G, Marrone A, Giordano M, Rinaldi L. Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients. J Gastroenterol Hepatol. 2018;33:1379-1382. [PMID: 29228501 DOI: 10.1111/jgh.14067] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 13.7] [Reference Citation Analysis]
75 Brandman D, Bacchetti P, Ayala CE, Maher JJ, Khalili M. Impact of insulin resistance on HCV treatment response and impact of HCV treatment on insulin sensitivity using direct measurements of insulin action. Diabetes Care. 2012;35:1090-1094. [PMID: 22399695 DOI: 10.2337/dc11-1837] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
76 Abdel Alem S, Elsharkawy A, Fouad R, Adel E, Abdellatif Z, Musa S, Nagy A, Hussein MS, Yosry A, Esmat G. Improvement of glycemic state among responders to Sofosbuvir-based treatment regimens: Single center experience. J Med Virol. 2017;89:2181-2187. [PMID: 28688190 DOI: 10.1002/jmv.24897] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
77 Todorovska B, Caloska-Ivanova V, Dimitrova-Genadieva M, Trajkovska M, Popova-Jovanovska R, Grivceva-Stardelova K, Licoska-Josifovic F, Andreevski V, Curakova-Ristovska E, Joksimovic N. Atorvastatin in Combination with Pegylated Interferon and Ribavirin Provided High Rate of Sustained Virological Response in Patients with Genotype 3 Hepatitis C Virus. Open Access Maced J Med Sci 2019;7:1641-8. [PMID: 31210815 DOI: 10.3889/oamjms.2019.459] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
78 Adinolfi LE, Restivo L, Zampino R, Lonardo A, Loria P. Metabolic alterations and chronic hepatitis C: treatment strategies. Expert Opin Pharmacother. 2011;12:2215-2234. [PMID: 21883025 DOI: 10.1517/14656566.2011.597742] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 5.0] [Reference Citation Analysis]
79 Shiffman ML, Gunn NT. Impact of hepatitis C virus therapy on metabolism and public health. Liver Int 2017;37 Suppl 1:13-8. [PMID: 28052632 DOI: 10.1111/liv.13282] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
80 Patel JH, Cobbold JF, Thomas HC, Taylor-Robinson SD. Hepatitis C and hepatic steatosis. QJM. 2010;103:293-303. [PMID: 20139103 DOI: 10.1093/qjmed/hcp192] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
81 Liang J, Lv C, Chen M, Xu M, Zhao C, Yang Y, Wang J, Zhu D, Gao J, Rong R, Zhu T, Yu M. Effects of preoperative hepatitis B virus infection, hepatitis C virus infection, and coinfection on the development of new-onset diabetes after kidney transplantation. J Diabetes 2019;11:370-8. [PMID: 30203544 DOI: 10.1111/1753-0407.12853] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
82 Lingala S, Ghany MG. Natural History of Hepatitis C. Gastroenterol Clin North Am. 2015;44:717-734. [PMID: 26600216 DOI: 10.1016/j.gtc.2015.07.003] [Cited by in Crossref: 101] [Cited by in F6Publishing: 82] [Article Influence: 16.8] [Reference Citation Analysis]
83 Lo Re V. Extrahepatic Complications of Hepatitis C Virus Infection in HIV and the Impact of Successful Antiviral Treatment. Clin Infect Dis 2017;64:498-500. [PMID: 28172488 DOI: 10.1093/cid/ciw814] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
84 Soverini V, Persico M, Bugianesi E, Forlani G, Salamone F, Massarone M, La Mura V, Mazzotti A, Bruno A, Marchesini G. HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas. Acta Diabetol. 2011;48:337-343. [PMID: 21574001 DOI: 10.1007/s00592-011-0293-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
85 Lapumnuaypol K, Pisarcik D, Putthapiban P, Sukhumthammarat W, Wijarnpreecha K, Thongprayoon C, Ungprasert P. Direct-acting antiviral agents decrease haemoglobin A1c level in patients with diabetes infected with hepatitis C virus: A systematic review & meta-analysis. Indian J Med Res 2020;152:562-7. [PMID: 34145095 DOI: 10.4103/ijmr.IJMR_1088_18] [Reference Citation Analysis]
86 Gastaldi G, Goossens N, Clément S, Negro F. Current level of evidence on causal association between hepatitis C virus and type 2 diabetes: A review. J Adv Res 2017;8:149-59. [PMID: 28149650 DOI: 10.1016/j.jare.2016.11.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
87 Negro F. Peroxisome proliferator-activated receptors and hepatitis C virus-induced insulin resistance. PPAR Res. 2009;2009:483485. [PMID: 19132131 DOI: 10.1155/2009/483485] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
88 Pattullo V, Duarte-Rojo A, Soliman W, Vargas-Vorackova F, Sockalingam S, Fantus IG, Allard J, Heathcote J. A 24-week dietary and physical activity lifestyle intervention reduces hepatic insulin resistance in the obese with chronic hepatitis C. Liver Int. 2013;33:410-419. [PMID: 23278982 DOI: 10.1111/liv.12041] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
89 Li M, Zhou H, Guan Y, Peng H, Wang S, Zhang P, Su B. Positive hepatitis B surface antibody is associated with reduced risk of diabetes mellitus in retired female Chinese workers. J Diabetes 2016;8:158-61. [PMID: 26016384 DOI: 10.1111/1753-0407.12317] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
90 Kawaguchi Y, Mizuta T. Interaction between hepatitis C virus and metabolic factors. World J Gastroenterol. 2014;20:2888-2901. [PMID: 24659880 DOI: 10.3748/wjg.v20.i11.2888] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
91 Bugianesi E, Salamone F, Negro F. The interaction of metabolic factors with HCV infection: does it matter? J Hepatol. 2012;56 Suppl 1:S56-S65. [PMID: 22300466 DOI: 10.1016/s0168-8278(12)60007-5] [Cited by in Crossref: 124] [Cited by in F6Publishing: 44] [Article Influence: 13.8] [Reference Citation Analysis]
92 Broker M, Frager SZ, Patel NS, Lebovics E, Frishman WH. The Inflammatory Relationship Between Hepatitis C Virus With Coronary and Carotid Atherosclerosis. Cardiol Rev 2021;29:178-83. [PMID: 32618587 DOI: 10.1097/CRD.0000000000000314] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
93 Adinolfi LE, Petta S, Fracanzani AL, Nevola R, Coppola C, Narciso V, Rinaldi L, Calvaruso V, Pafundi PC, Lombardi R, Staiano L, Di Marco V, Solano A, Marrone A, Saturnino M, Rini F, Guerrera B, Troina G, Giordano M, Craxì A, Sasso FC. Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct‐acting antiviral therapy: A prospective study. Diabetes Obes Metab 2020;22:2408-16. [DOI: 10.1111/dom.14168] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
94 Cesari M, Caramma I, Antinori S, Adorni F, Galli M, Milazzo L. Impact of hyperglycaemia and cholesterol levels on the outcome of hepatitis C virus (HCV) treatment in HIV/HCV-coinfected patients. HIV Med 2009;10:580-5. [PMID: 19785667 DOI: 10.1111/j.1468-1293.2009.00729.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
95 Alaei M, Negro F. Hepatitis C virus and glucose and lipid metabolism. Diabetes & Metabolism 2008;34:692-700. [DOI: 10.1016/s1262-3636(08)74606-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
96 Cacciola I, Russo G, Filomia R, Pitrone C, Caccamo G, Giandalia A, Alibrandi A, Stella Franzè M, Porcari S, Maimone S, Saitta C, Squadrito G, Raimondo G. Over time evaluation of glycaemic control in direct-acting antiviral-treated hepatitis C virus/diabetic individuals with chronic hepatitis or with cirrhosis. Liver Int 2021;41:2059-67. [PMID: 33894103 DOI: 10.1111/liv.14905] [Reference Citation Analysis]
97 Hsu C, Kao J, Chao Y, Lin HH, Fan Y, Huang C, Tsai P. Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan. Aliment Pharmacol Ther 2013;38:415-23. [DOI: 10.1111/apt.12391] [Cited by in Crossref: 85] [Cited by in F6Publishing: 81] [Article Influence: 10.6] [Reference Citation Analysis]
98 Tsai MC, Kao KL, Huang HC, Chen W, Fang CK, Sung FC, Wu SI, Stewart R. Incidence of Type 2 Diabetes in Patients With Chronic Hepatitis C Receiving Interferon-Based Therapy. Diabetes Care 2020;43:e63-4. [PMID: 32209648 DOI: 10.2337/dc19-1704] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
99 Ponziani FR, Milani A, Gasbarrini A, Zaccaria R, Viganò R, Iemmolo RM, Donato MF, Rendina M, Toniutto P, Pasulo L. AISF RECOLT C- Group. Treatment of genotype-1 hepatitis C recurrence after liver transplant improves surivival in both sustained responders and relapsers. Transplant Int. 2013;26:281-289. [PMID: 23230956 DOI: 10.1111/tri.12027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
100 Kukla M, Piotrowski D, Waluga M, Hartleb M. Insulin resistance and its consequences in chronic hepatitis C. Clin Exp Hepatol. 2015;1:17-29. [PMID: 28856251 DOI: 10.5114/ceh.2015.51375] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
101 Drazilova S, Gazda J, Janicko M, Jarcuska P. Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy. Can J Gastroenterol Hepatol 2018;2018:6150861. [PMID: 30186821 DOI: 10.1155/2018/6150861] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
102 Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Hirakawa M, Saito S, Ikeda K, Kobayashi M, Kumada H, Kobayashi T. Losartan reduces the onset of type 2 diabetes in hypertensive Japanese patients with chronic hepatitis C. J Med Virol 2009;81:1584-90. [PMID: 19623665 DOI: 10.1002/jmv.21572] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
103 Zhang W, Rao HY, Feng B, Liu F, Wei L. Effects of interferon-alpha treatment on the incidence of hyperglycemia in chronic hepatitis C patients: a systematic review and meta-analysis. PLoS One. 2012;7:e39272. [PMID: 22768067 DOI: 10.1371/journal.pone.0039272] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
104 Negro F, Alaei M. Hepatitis C virus and type 2 diabetes. World J Gastroenterol. 2009;15:1537-1547. [PMID: 19340895 DOI: 10.3748/wjg.15.1537] [Cited by in CrossRef: 85] [Cited by in F6Publishing: 81] [Article Influence: 7.1] [Reference Citation Analysis]
105 Desbois AC, Cacoub P. Diabetes mellitus, insulin resistance and hepatitis C virus infection: A contemporary review. World J Gastroenterol. 2017;23:1697-1711. [PMID: 28321170 DOI: 10.3748/wjg.v23.i9.1697] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 38] [Article Influence: 11.3] [Reference Citation Analysis]
106 Giordanino C, Ceretto S, Bo S, Smedile A, Ciancio A, Bugianesi E, Pellicano R, Fagoonee S, Versino E, Costa G. Type 2 diabetes mellitus and chronic hepatitis C: which is worse? Results of a long-term retrospective cohort study. Dig Liver Dis. 2012;44:406-412. [PMID: 22245505 DOI: 10.1016/j.dld.2011.12.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
107 Goossens N, Negro F. The impact of obesity and metabolic syndrome on chronic hepatitis C. Clin Liver Dis. 2014;18:147-156. [PMID: 24274870 DOI: 10.1016/j.cld.2013.09.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
108 European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60:392-420. [PMID: 24331294 DOI: 10.1016/j.jhep.2013.11.003] [Cited by in Crossref: 600] [Cited by in F6Publishing: 545] [Article Influence: 75.0] [Reference Citation Analysis]
109 Huang JF, Yu ML, Huang CF, Juo SH, Dai CY, Hsieh MY, Hou NJ, Yeh ML, Hsieh MH, Yang JF. The outcomes of glucose abnormalities in pre-diabetic chronic hepatitis C patients receiving peginterferon plus ribavirin therapy. Liver Int. 2012;32:962-969. [PMID: 22356575 DOI: 10.1111/j.1478-3231.2012.02771.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
110 Coelho HSM, Villela-nogueira CA. Predictors of response to chronic hepatitis C treatment. Annals of Hepatology 2010;9:S54-60. [DOI: 10.1016/s1665-2681(19)31725-9] [Cited by in Crossref: 10] [Article Influence: 0.9] [Reference Citation Analysis]
111 Morales AL, Junga Z, Singla MB, Sjogren M, Torres D. Hepatitis C eradication with sofosbuvir leads to significant metabolic changes. World J Hepatol. 2016;8:1557-1563. [PMID: 28050236 DOI: 10.4254/wjh.v8.i35.1557] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
112 Souza AF, Pace FH, Chebli JM, Ferreira LE. Insulin resistance in non-diabetic patients with chronic hepatitis C: what does it mean? Arq Bras Endocrinol Metabol 2011;55:412-8. [PMID: 22011858 DOI: 10.1590/s0004-27302011000600008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
113 Yair-Sabag S, Nussinson E, Ben-Assuli O, Shibli F, Shahbari A, Zelber-Sagi S. Retrospective study of the associations between hepatitis C virus infection and metabolic factors. World J Hepatol. 2016;8:1269-1278. [PMID: 27843537 DOI: 10.4254/wjh.v8.i30.1269] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
114 Negro F. Facts and fictions of HCV and comorbidities: Steatosis, diabetes mellitus, and cardiovascular diseases. Journal of Hepatology 2014;61:S69-78. [DOI: 10.1016/j.jhep.2014.08.003] [Cited by in Crossref: 95] [Cited by in F6Publishing: 82] [Article Influence: 13.6] [Reference Citation Analysis]